Kumamoto University | HIV drug lenacapavir found to disrupt virus formation, creating giant non-infectious particles

Back to the "HIV and Co-Infections News" list

Joint Japanese research reveals a second mechanism behind the drug’s powerful antiviral activity, offering new insights for developing next-generation HIV treatments.

Kumamoto University news release

Lenacapavir is a powerful, long-acting drug used to prevent and treat HIV infection. While it is known to block key steps in the virus’s replication after entering a cell, researchers have now uncovered another way the drug works: it disrupts the formation of new virus particles, causing them to become abnormally large and non-infectious.

Read the full news release here.

 

Source : EurekAlert!

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.